Amubarvimab

Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants[1][2].

Product Specifications

CAS Number

[2509447-07-6]

Product Name Alternative

BRII-196

UNSPSC

12352203

Target

SARS-CoV

Type

Inhibitory Antibodies

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/amubarvimab.html

Purity

95.00

Solubility

H2O

Smiles

[Amubarvimab]

Molecular Weight

(143.84 kDa)

References & Citations

[1]Ji Y, et, al. Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2. Front Immunol. 2022 Sep 14;13:980435. |[2]Hoy SM. Amubarvimab/Romlusevimab: First Approval. Drug. 2022 Aug;82 (12) :1327-1331.